Inactive Instrument

RELIEF THERAPEUTICS Holding SA Stock CINNOBER BOAT

Equities

0QKQ

CH0100191136

Biotechnology & Medical Research

Financials

Sales 2022 6.08M 6.74M 9.18M Sales 2023 6.03M 6.68M 9.1M Capitalization 24.96M 27.64M 37.66M
Net income 2022 -50M -55.38M -75.46M Net income 2023 -98M -109M -148M EV / Sales 2022 19.3 x
Net cash position 2022 14.89M 16.5M 22.48M Net cash position 2023 10.25M 11.36M 15.47M EV / Sales 2023 2.44 x
P/E ratio 2022
-2.5 x
P/E ratio 2023
-0.24 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 65.87%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 55 22-01-27
Chairman 45 16-05-24
Corporate Officer/Principal - 21-11-30
Members of the board TitleAgeSince
Chairman 45 16-05-24
Corporate Officer/Principal 59 21-05-26
Chief Executive Officer 55 22-01-27
More insiders
RELIEF THERAPEUTICS Holding SA is a Switzerland-based biopharmaceutical company. The Company’s objective is to provide patients with therapeutic relief in serious diseases with high unmet medical need, as well as to focus on developing treatments for respiratory diseases. It specializes in clinical-stage projects based on molecules of natural origin (peptides and proteins with a history of clinical use and either initial human activity with efficacy data or a strong scientific rationale. Its lead compound is RLF-100 (aviptadil), a synthetic human vasoactive intestinal peptide (VIP) with a multifaceted mode of action in respiratory indications. RLF-100 is being investigated in two placebo-controlled U.S. phase 2b/3 clinical trials in respiratory deficiency due to COVID-19. Its RLF-100 is also used for pulmonary sarcoidosis. The Company is also involved in the clinical development of RLF-100 that is in planning stage for other indications in acute and chronic lung diseases.
Calendar
More about the company